Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913535 | 0.88 | ABHD6 (0.49) | ESR1ESR2ABHD6ACKR3EP300 | |
| SCHEMBL13539116 | 0.84 | TIPARP (0.41) | ABHD6TIPARP | |
| SCHEMBL16147790 | 0.83 | TMEM97 (0.41) | ABHD6 | |
| SCHEMBL25604192 | 0.82 | ESR1 (0.56) | ESR1ESR2ABHD6EP300CREBBP | |
| SCHEMBL30261507 | 0.82 | NOTUM (0.58) | EP300CREBBP | |
| SCHEMBL14678121 | 0.81 | ESR1 (0.44) | ESR1ESR2ABHD6ACKR3EP300 | |
| SCHEMBL3885156 | 0.81 | ESR1 (0.51) | ESR1ESR2ABHD6ACKR3EP300 | |
| SCHEMBL17130540 | 0.81 | ESR1 (0.55) | ESR1ESR2ABHD6EP300CREBBP | |
| SCHEMBL587897 | 0.81 | ABHD6 (0.69) | ESR1ESR2ABHD6EP300CREBBP | |
| SCHEMBL9913536 | 0.78 | ESR2 (0.52) | ESR2ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198274-B2 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198274-B2 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | MAOB, MAOA, TPH1 | ESR1 2065/4885ESR2 2745/4885ABHD6 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.